Home » Stocks » DMTK

DermTech, Inc. (DMTK)

Stock Price: $37.75 USD -5.71 (-13.14%)
Updated Apr 19, 2021 12:27 PM EDT - Market open
Market Cap 1.25B
Revenue (ttm) 5.89M
Net Income (ttm) -35.25M
Shares Out 28.76M
EPS (ttm) -3.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $37.75
Previous Close $43.46
Change ($) -5.71
Change (%) -13.14%
Day's Open 42.65
Day's Range 37.27 - 42.85
Day's Volume 1,144,123
52-Week Range 9.64 - 84.49

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Think long-term with this dermatology company.

3 weeks ago - The Motley Fool

There are lots of reasons to be excited about DermTech's breakthrough diagnostic technology.

1 month ago - The Motley Fool

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 11.11% and 24.77%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported financial results for th...

1 month ago - Business Wire

The wind is definitely at the backs of these high-flying stocks.

Other stocks mentioned: ETSY, SKLZ
1 month ago - The Motley Fool

There aren't any obstacles in sight for these great stocks.

Other stocks mentioned: CRLBF, GHVIU
1 month ago - The Motley Fool

This high-flying healthcare stock should have more room to run.

1 month ago - The Motley Fool

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that four of its abstra...

1 month ago - Business Wire

Dermtech stock is up over 130% so far in 2021, and increased insurance acceptance is just one reason it could be a five-bagger in the next five years.

Other stocks mentioned: ABBV, AZN, JNJ, LRLCY
1 month ago - The Motley Fool

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it plans to release its...

2 months ago - Business Wire

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management wil...

2 months ago - Business Wire

All three companies are multi-baggers in the last year and have more room to run.

Other stocks mentioned: PERI, PRTS
2 months ago - The Motley Fool

Shares of the skin-cancer genomics company gained as it opened up a new customer base.

2 months ago - The Motley Fool

DermTech Inc (NASDAQ: DMTK) shares were soaring to a new high Thursday after the company unveiled a contract with Blue Cross Blue Shield of Texas for its melanoma gene express test. What Happened: La Jo...

2 months ago - Benzinga

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has contracted, effe...

2 months ago - Business Wire

Investor excitement mounted around the skin-care detection specialist.

2 months ago - The Motley Fool

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the additions of Dr. Li...

2 months ago - Business Wire

They don't need a short squeeze to skyrocket.

Other stocks mentioned: CRLBF, SKLZ
2 months ago - The Motley Fool

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that DermTech managemen...

2 months ago - Business Wire

The shortest month is a great time to go long with these great stocks.

Other stocks mentioned: FVRR, IPOE
2 months ago - The Motley Fool

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its support and present...

2 months ago - Business Wire

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its presentation at the...

2 months ago - Business Wire

You might not hear much about them, but that could be a good thing.

Other stocks mentioned: BLL, TRUP
3 months ago - The Motley Fool

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...

Other stocks mentioned: CAG, ALDX, FATE, GBIO, MRSN, ORI, REVG ...
3 months ago - Benzinga

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that SKIN has published...

3 months ago - Business Wire

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that non-invasive genom...

3 months ago - Business Wire

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the closing of its prev...

3 months ago - Business Wire

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the pricing of its prev...

3 months ago - Business Wire

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it has commenced a...

3 months ago - Business Wire

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the appointment of Ray ...

3 months ago - Business Wire

The biotech's skin cancer diagnostic tool is a significant improvement over the standard of care.

3 months ago - The Motley Fool

The company's genomic test for melanoma won another positive coverage decision.

3 months ago - The Motley Fool

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that Geisinger Health S...

3 months ago - Business Wire

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ:DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that DermTech management...

3 months ago - Business Wire

DermTech (DMTK) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

3 months ago - Zacks Investment Research

No news was good news.

3 months ago - The Motley Fool

DermTech's PLA stickers can help to diagnose melanoma despite being lower cost, more accurate, and less invasive compared to standard surgical biopsies.With 4-4.5mil surgical biopsies per year and an av...

3 months ago - Seeking Alpha

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the topline results fro...

4 months ago - Business Wire

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its inclusion in two CM...

4 months ago - Business Wire

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has entered into an ...

4 months ago - Business Wire

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the presentation of a p...

4 months ago - Business Wire

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has entered into an ...

4 months ago - Business Wire

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech Presents New Clinical Research Abstract at the 2020 Fall Clinical Dermatology Conference

5 months ago - Business Wire

Great things appear to be in store for these rising stars.

Other stocks mentioned: IIPR, TRUP
5 months ago - The Motley Fool

DermTech, Inc. (DMTK) CEO John Dobak on Q3 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported unaudited financial resu...

5 months ago - Business Wire

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that C...

5 months ago - Business Wire

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech to Announce Third Quarter 2020 Financial Results on November 10, 2020

5 months ago - Business Wire

Discover how these three companies could change the face of healthcare.

Other stocks mentioned: SMLR, TRUP
5 months ago - The Motley Fool

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech Announces Appointment of Chief Scientific Officer

7 months ago - Business Wire

About DMTK

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th... [Read more...]

Industry
Diagnostics & Research
Stock Exchange
NASDAQ
Ticker Symbol
DMTK
Full Company Profile

Financial Performance

In 2020, DermTech's revenue was $5.89 million, an increase of 74.94% compared to the previous year's $3.36 million. Losses were -$35.25 million, 79.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for DermTech stock is "Strong Buy." The 12-month stock price forecast is 64.25, which is an increase of 70.20% from the latest price.

Price Target
$64.25
(70.20% upside)
Analyst Consensus: Strong Buy